Rodriguez-Lozano
FJ, O–ate-S‡nchez RE. Treatment of osteonecrosis of the jaw
related to bisphosphonates and other
antiresorptive agents. Med Oral Patol Oral Cir Bucal.
2016 Sep 1;21 (5):e595-600.
doi:10.4317/medoral.20980
http://dx.doi.org/doi:10.4317/medoral.20980
|
1. Ruggiero SL, Dodson TB, Fantasia
J, Goodday R, Aghaloo T, Mehrotra B, et al. American Association of Oral and
Maxillofacial Surgeons Position Paper on Medication-Related Osteonecrosis of
the Jaw-2014 Update. J Oral Maxillofac Surg. 2014;72:1938-56. |
|
|
|
|
|
2. Ruggiero SL, Dodson TB, Assael LA,
Landesberg R, Marx RE, Mehrotra B. American Association of Oral and
Maxillofacial Surgeons Position Paper on Bisphosphonate-Related Osteonecrosis
of the Jaws-2009 Update. Journal of Oral and Maxillofacial Surgery. 2009;67:2-12. |
|
|
|
|
|
3. Marx RE. Pamidronate (Aredia) and
zoledronate (Zometa) induced avascular necrosis of the jaws: a growing
epidemic. J Oral Maxillofac Surg. 2003;61:1115-7. |
|
|
|
|
|
4. Ripamonti CI, Maniezzo M, Campa T,
Fagnoni E, Brunelli C, Saibene G, et al. Decreased occurrence of
osteonecrosis of the jaw after implementation of dental preventive measures
in solid tumour patients with bone metastases treated with bisphosphonates.
The experience of the National Cancer Institute of Milan. Ann Oncol.
2009;20:137-45. |
|
|
|
|
|
5. Dimopoulos MA, Kastritis E, Bamia
C, Melakopoulos I, Gika D, Roussou M, et al. Reduction of osteonecrosis of
the jaw (ONJ) after implementation of preventive measures in patients with
multiple myeloma treated with zoledronic acid. Ann Oncol. 2009;20:117-20. |
|
|
|
|
|
6. Bagan JV, Jimenez Y, Murillo J,
Hernandez S, Poveda R, Sanchis JM, et al. Jaw osteonecrosis associated with
bisphosphonates: multiple exposed areas and its relationship to teeth
extractions. Study of 20 cases. Oral Oncol. 2006;42:327-9. |
|
|
|
|
|
7. Rupel K, Ottaviani G, Gobbo M,
Contardo L, Tirelli G, Vescovi P, et al. A systematic review of therapeutical
approaches in bisphosphonates-related osteonecrosis of the jaw (BRONJ). Oral
Oncol. 2014;50:1049-57. |
|
|
|
|
|
8. Ruggiero SL, Mehrotra B, Rosenberg
TJ, Engroff SL. Osteonecrosis of the jaws associated with the use of
bisphosphonates: a review of 63 cases. J Oral Maxillofac Surg.
2004;62:527-34. |
|
|
|
|
|
9. Gonz‡lvez-Garc’a M,
Rodr’guez-Lozano FJ, Villanueva V, Segarra-Fenoll D, Rodr’guez-Gonz‡lez MA,
O-ate-S‡nchez R, et al. Cell therapy in bisphosphonate-related osteonecrosis
of the jaw. J Craniofac Surg. 2013;24:e226-8. |
|
|
|
|
|
10. Ruggiero SL, Fantasia J, Carlson
E. Bisphosphonate-related osteonecrosis of the jaw: background and guidelines
for diagnosis, staging and management. Oral Surg Oral Med Oral Pathol Oral
Radiol Endod. 2006;102:433-41. |
|
|
|
|
|
11. Ruggiero SL. Guidelines for the
diagnosis of bisphosphonate-related osteonecrosis of the jaw (BRONJ). Clin
Cases Miner Bone Metab. 2007;4:37-42. |
|
|
|
|
|
12. Ristow O, Otto S, Troeltzsch M,
Hohlweg-Majert B, Pautke C. Treatment perspectives for medication-related
osteonecrosis of the jaw (MRONJ). J Craniomaxillofac Surg. 2015;43:290-3. |
|
|
|
|
|
13. Liberati A, Altman DG, Tetzlaff
J, Mulrow C, G¿tzsche PC, Ioannidis JP, et al. The PRISMA statement for
reporting systematic reviews and meta-analyses of studies that evaluate
health care interventions: explanation and elaboration. J Clin Epidemiol.
2009;62:e1-34. |
|
|
|
|
|
14. Lerman MA, Xie W, Treister NS,
Richardson PG, Weller EA, Woo SB. Conservative management of
bisphosphonate-related osteonecrosis of the jaws: staging and treatment
outcomes. Oral Oncol. 2013;49:977-83. |
|
|
|
|
|
15. Melea PI, Melakopoulos I,
Kastritis E, Tesseromatis C, Margaritis V, Dimopoulos MA, et al. Conservative
treatment of bisphosphonate-related osteonecrosis of the jaw in multiple
myeloma patients. Int J Dent. 2014;2014:427273. |
|
|
|
|
|
16. Vescovi P, Merigo E, Meleti M,
Manfredi M, Fornaini C, Nammour S, et al. Conservative surgical management of
stage I bisphosphonate-related osteonecrosis of the jaw. Int J Dent.
2014;2014:107690. |
|
|
|
|
|
17. Ripamonti CI, Cislaghi E, Mariani
L, Maniezzo M. Efficacy and safety of medical ozone (O (3)) delivered in oil
suspension applications for the treatment of osteonecrosis of the jaw in
patients with bone metastases treated with bisphosphonates: Preliminary
results of a phase I-II study. Oral Oncol. 2011;47:185-90. |
|
|
|
|
|
18. Freiberger JJ, Padilla-Burgos R,
McGraw T, Suliman HB, Kraft KH, Stolp BW, et al. What is the role of
hyperbaric oxygen in the management of bisphosphonate-related osteonecrosis
of the jaw: a randomized controlled trial of hyperbaric oxygen as an adjunct
to surgery and antibiotics. J Oral Maxillofac Surg. 2012;70:1573-83. |
|
|
|
|
|
19. Atalay B, Yalcin S, Emes Y, Aktas
I, Aybar B, Issever H, et al. Bisphosphonate-related osteonecrosis:
laser-assisted surgical treatment or conventional surgery?. Lasers Med Sci.
2011;26:815-23. |
|
|
|
|
|
20. Magremanne M, Reychler H.
Pentoxifylline and tocopherol in the treatment of yearly zoledronic
acid-related osteonecrosis of the jaw in a corticosteroid-induced
osteoporosis. J Oral Maxillofac Surg. 2014;72:334-7. |
|
|
|
|
|
21. Van den Wyngaert T, Claeys T,
Huizing MT, Vermorken JB, Fossion E. Initial experience with conservative
treatment in cancer patients with osteonecrosis of the jaw (ONJ) and
predictors of outcome. Ann Oncol. 2009;20:331-6. |
|
|
|
|
|
22. Scoletta M, Arduino PG, Dalmasso
P, Broccoletti R, Mozzati M. Treatment outcomes in patients with
bisphosphonate-related osteonecrosis of the jaws: a prospective study. Oral
Surg Oral Med Oral Pathol Oral Radiol Endod. 2010;110:46-53. |
|
|
|
|
|
23. Nicolatou-Galitis O, Papadopoulou
E, Sarri T, Boziari P, Karayianni A, Kyrtsonis MC, et al. Osteonecrosis of
the jaw in oncology patients treated with bisphosphonates: prospective
experience of a dental oncology referral center. Oral Surg Oral Med Oral
Pathol Oral Radiol Endod. 2011;112:195-202. |
|
|
|
|
|
24. Rugani P, Acham S, Kirnbauer B,
Truschnegg A, Obermayer-Pietsch B, Jakse N. Stage-related treatment concept
of medication-related osteonecrosis of the jaw-a case series. Clin Oral
Investig. 2015;19:1329-38. |
|
|
|
|
|
25. Williamson RA. Surgical
management of bisphosphonate induced osteonecrosis of the jaws. Int J Oral
Maxillofac Surg. 2010;39:251-5. |
|
|
|
|
|
26. Graziani F, Vescovi P, Campisi G,
Favia G, Gabriele M, Gaeta GM, et al. Resective surgical approach shows a
high performance in the management of advanced cases of
bisphosphonate-related osteonecrosis of the jaws: a retrospective survey of
347 cases. J Oral Maxillofac Surg. 2012;70:2501-7. |
|
|
|
|
|
27. Wutzl A, Biedermann E, Wanschitz
F, Seemann R, Klug C, Baumann A, et al. Treatment results of
bisphosphonate-related osteonecrosis of the jaws. Head Neck. 2008;30:1224-30. |
|
|
|
|
|
28. Vescovi P, Merigo E, Meleti M,
Manfredi M, Guidotti R, Nammour S. Bisphosphonates-related osteonecrosis of
the jaws: a concise review of the literature and a report of a single-centre
experience with 151 patients. J Oral Pathol Med. 2012;41:214-21. |
|
|
|
|
|
29. Martins MA, Martins MD, Lascala
CA, Curi MM, Migliorati CA, Tenis CA, et al. Association of laser phototherapy
with PRP improves healing of bisphosphonate-related osteonecrosis of the jaws
in cancer patients: a preliminary study. Oral Oncol. 2012;48:79-84. |
|
|
|
|
|
30. Thumbigere-Math V, Sabino MC,
Gopalakrishnan R, Huckabay S, Dudek AZ, Basu S, et al. Bisphosphonate-related
osteonecrosis of the jaw: clinical features, risk factors, management, and
treatment outcomes of 26 patients. J Oral Maxillofac Surg. 2009;67:1904-13. |
|
|
|
|
|
31. Bedogni A, Saia G, Bettini G,
Tronchet A, Totola A, Bedogni G, et al. Long-term outcomes of surgical
resection of the jaws in cancer patients with bisphosphonate-related
osteonecrosis. Oral Oncol. 2011;47:420-4. |
|
|
|
|
|
32. Voss PJ, Joshi Oshero J,
Kovalova-MŸller A, Veigel Merino EA, Sauerbier S, Al-Jamali J, et al.
Surgical treatment of bisphosphonate-associated osteonecrosis of the jaw:
technical report and follow up of 21 patients. J Craniomaxillofac Surg.
2012;40:719-25. |
|
|
|
|
|
33. Schubert M, Klatte I, Linek W,
MŸller B, Dšring K, Eckelt U, et al. The saxon bisphosphonate register -
therapy and prevention of bisphosphonate-related osteonecrosis of the jaws.
Oral Oncol. 2012;48:349-54. |
|
|
|
|
|
34. Carlson ER, Basile JD. The role
of surgical resection in the management of bisphosphonate-related
osteonecrosis of the jaws. J Oral Maxillofac Surg. 2009;67:85-95. |
|
|
|
|
|
35. Agrillo A, Filiaci F, Ramieri V,
Riccardi E, Quarato D, Rinna C, et al. Bisphosphonate-related osteonecrosis
of the jaw (BRONJ): 5 year experience in the treatment of 131 cases with
ozone therapy. Eur Rev Med Pharmacol Sci. 2012;16:1741-7. |
|
|
|
|
|
36. Montefusco V, Gay F, Spina F,
Miceli R, Maniezzo M, Teresa Ambrosini M, et al. Antibiotic prophylaxis
before dental procedures may reduce the incidence of osteonecrosis of the jaw
in patients with multiple myeloma treated with bisphosphonates. Leuk Lymphoma.
2008;49:2156-62. |
|
|
|
|
|
37. Cella L, Oppici A, Arbasi M,
Moretto M, Piepoli M, Vallisa D, et al. Autologous bone marrow stem cell
intralesional transplantation repairing bisphosphonate related osteonecrosis
of the jaw. Head Face Med. 2011;7:16. |
|
|
|
|
|
38. Curi MM, Cossolin GS, Koga DH,
Zardetto C, Christianini S, Feher O, et al. Bisphosphonate-related
osteonecrosis of the jaws--an initial case series report of treatment
combining partial bone resection and autologous platelet-rich plasma. J Oral
Maxillofac Surg. 2011;69:2465-72. |
|
|
|
|
|
39. Cheung A, Seeman E. Teriparatide
therapy for alendronate-associated osteonecrosis of the jaw. N Engl J Med.
2010;363:2473-4. |
|
|
|
|
|
40. Neuprez A, Rompen E, Crielaard
JM, Reginster JY. Teriparatide therapy for denosumab-induced osteonecrosis of
the jaw in a male osteoporotic patient. Calcif Tissue Int. 2014;95:94-6. |
|
|
|
|
|
41. Kim JW, Kim SJ, Kim MR.
Leucocyte-rich and platelet-rich fibrin for the treatment of
bisphosphonate-related osteonecrosis of the jaw: a prospective feasibility
study. Br J Oral Maxillofac Surg. 2014;52:854-9. |
|
|
|
|